Author

Moreniola Akande

Washington University in St. Louis

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Organism:mouse· 1

Frequent Co-Authors

Andrea R. HagemanniD· 1 shared Benjamin Guy BitleriD· 1 shared Bisiayo FashemiiD· 1 shared Brooke E. SandersiD· 1 shared Carolyn Kay McCourtiD· 1 shared David Gardner MutchiD· 1 shared Dineo KhabeleiD· 1 shared Elizabeth BabuiD· 1 shared

Activity by Year

2025-2025 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

Andrea R. HagemannORCID

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

Targeting RAD52 overcomes PARP inhibitor resistance in preclinical Brca2-deficient ovarian cancer model

Yukihide Ota, Vijayalaxmi G. Gupta, Bisiayo Fashemi, Moreniola Akande, Elizabeth Babu, Prasanth Thuthika, Maia Lina Elizagaray, Lulu Sun, Brooke E. Sanders, Lindsay M. Kuroki, Carolyn Kay McCourt, Andrea R. Hagemann, Ian S. Hagemann, Premal H. Thaker, David Gardner Mutch, , Dineo Khabele

This study identifies RAD52 as a target to overcome PARP inhibitor resistance in BRCA2-deficient ovarian cancer by showing its role in DNA repair and demonstrating synergistic effects with PARP inhibitors.

bioRxiv · Sep 24, 2025 · PreprintCancer Biology